{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:19:34Z","timestamp":1773674374309,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T00:00:00Z","timestamp":1180310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T00:00:00Z","timestamp":1180310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2007,5,28]]},"DOI":"10.1038\/sj.onc.1210368","type":"journal-article","created":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T10:07:46Z","timestamp":1180346866000},"page":"3699-3703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia\/lymphoma"],"prefix":"10.1038","volume":"26","author":[{"given":"T A","family":"Waldmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,28]]},"reference":[{"key":"BF1210368_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJM200003023420902","volume":"342","author":"A Beniaminovitz","year":"2000","unstructured":"Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD et al. (2000). Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342: 613\u2013619.","journal-title":"N Engl J Med"},{"key":"BF1210368_CR2","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1073\/pnas.0601335103","volume":"103","author":"B Bielekova","year":"2006","unstructured":"Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA et al. (2006). Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103: 5941\u20135946.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1210368_CR3","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.1073\/pnas.0402653101","volume":"101","author":"B Bielekova","year":"2004","unstructured":"Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J et al. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101: 8705\u20138708.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1210368_CR4","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.4049\/jimmunol.133.6.3054","volume":"133","author":"JM Depper","year":"1984","unstructured":"Depper JM, Leonard WJ, Kronke M, Noguchi PD, Cunningham RE, Waldmann TA et al. (1984). Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 133: 3054\u20133061.","journal-title":"J Immunol"},{"key":"BF1210368_CR5","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/00007890-200005150-00022","volume":"69","author":"DE Eckhoff","year":"2000","unstructured":"Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C et al. (2000). The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 69: 1867\u20131872.","journal-title":"Transplantation"},{"key":"BF1210368_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1359-6101(00)00028-9","volume":"12","author":"KT Jeang","year":"2001","unstructured":"Jeang KT . (2001). Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 12: 207\u2013217.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BF1210368_CR7","first-page":"1495","volume":"50","author":"RP Junghans","year":"1990","unstructured":"Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C . (1990). Anti-Tac-H a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50: 1495\u20131502.","journal-title":"Cancer Res"},{"key":"BF1210368_CR8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","volume":"18","author":"RJ Kreitman","year":"2000","unstructured":"Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S et al. (2000). Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18: 1622\u20131636.","journal-title":"J Clin Oncol"},{"key":"BF1210368_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1067\/mjd.2000.106515","volume":"43","author":"JG Krueger","year":"2000","unstructured":"Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S et al. (2000). Successful in vivo blockade of CD25 (high-affinity interleukin-2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448\u2013458.","journal-title":"J Am Acad Dermatol"},{"key":"BF1210368_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/ana.410440613","volume":"44","author":"TJ Lehky","year":"1998","unstructured":"Lehky TJ, Levin MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS et al. (1998). Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy\/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 44: 942\u2013947.","journal-title":"Ann Neurol"},{"key":"BF1210368_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/311626a0","volume":"311","author":"WJ Leonard","year":"1984","unstructured":"Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ et al. (1984). Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311: 626\u2013631.","journal-title":"Nature"},{"key":"BF1210368_CR12","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/S0021-9258(18)89674-0","volume":"260","author":"WJ Leonard","year":"1985","unstructured":"Leonard WJ, Depper JM, Kronke M, Robb RJ, Waldmann TA, Greene WC . (1985). The human receptor for T-cell growth factor. Evidence for variable post-translational processing phosphorylation sulfation and the ability of precursor forms of the receptor to bind T-cell growth factor. J Biol Chem 260: 1872\u20131880.","journal-title":"J Biol Chem"},{"key":"BF1210368_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/300267a0","volume":"300","author":"WJ Leonard","year":"1982","unstructured":"Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC . (1982). A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor: partial characterization of the receptor. Nature 300: 267\u2013269.","journal-title":"Nature"},{"key":"BF1210368_CR14","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.4049\/jimmunol.174.9.5187","volume":"174","author":"Z Li","year":"2005","unstructured":"Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB . (2005). Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174: 5187\u20135191.","journal-title":"J Immunol"},{"key":"BF1210368_CR15","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1182\/blood-2003-04-1032","volume":"102","author":"JP Maciejewski","year":"2003","unstructured":"Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS . (2003). Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 102: 3584\u20133586.","journal-title":"Blood"},{"issue":"Suppl 1","key":"BF1210368_CR16","doi-asserted-by":"publisher","first-page":"i109","DOI":"10.1136\/ard.59.suppl_1.i109","volume":"59","author":"JC Morris","year":"2000","unstructured":"Morris JC, Waldmann TA . (2000). Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 59 (Suppl 1): i109\u2013i114.","journal-title":"Ann Rheum Dis"},{"key":"BF1210368_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00007890-199901150-00019","volume":"67","author":"B Nashan","year":"1999","unstructured":"Nashan B, Light S, Hardie IR, Lin A, Johnson JR . (1999). Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 67: 110\u2013115.","journal-title":"Transplantation"},{"key":"BF1210368_CR18","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","volume":"96","author":"RB Nussenblatt","year":"1999","unstructured":"Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van VP et al. (1999). Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial. Proc Natl Acad Sci USA 96: 7462\u20137466.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1210368_CR19","first-page":"98P","volume":"47","author":"D O'Mahony","year":"2006","unstructured":"O'Mahony D, Morris JC, Carrasquillo JA, Le N, Paik CH, Whatley M et al. (2006). Phase I\/II study of Yttrium-90 labeled humanized anti-Tac (HAT) monoclonal antibody and calcium DTPA in CD25-expressing malignancies. J Nucl Med 47: 98P.","journal-title":"J Nucl Med"},{"key":"BF1210368_CR20","first-page":"6977","volume":"60","author":"KE Phillips","year":"2000","unstructured":"Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK et al. (2000). IL-2R alpha directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2R alpha interaction. Cancer Res 60: 6977\u20136984.","journal-title":"Cancer Res"},{"key":"BF1210368_CR21","doi-asserted-by":"publisher","first-page":"10029","DOI":"10.1073\/pnas.86.24.10029","volume":"86","author":"C Queen","year":"1989","unstructured":"Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF et al. (1989). A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86: 10029\u201310033.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1210368_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.7326\/0003-4819-113-8-619","volume":"113","author":"LA Rubin","year":"1990","unstructured":"Rubin LA, Nelson DL . (1990). The soluble interleukin-2 receptor: biology function and clinical application. Ann Intern Med 113: 619\u2013627.","journal-title":"Ann Intern Med"},{"key":"BF1210368_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJM200007273430401","volume":"343","author":"AM Shapiro","year":"2000","unstructured":"Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL et al. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230\u2013238.","journal-title":"N Engl J Med"},{"key":"BF1210368_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1126\/science.3095922","volume":"234","author":"M Sharon","year":"1986","unstructured":"Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ . (1986). Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 234: 859\u2013863.","journal-title":"Science"},{"key":"BF1210368_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/0003-4819-144-3-200602070-00006","volume":"144","author":"EM Sloand","year":"2006","unstructured":"Sloand EM, Scheinberg P, Maciejewski J, Young NS . (2006). Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med 144: 181\u2013185.","journal-title":"Ann Intern Med"},{"key":"BF1210368_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev.immunol.14.1.179","volume":"14","author":"K Sugamura","year":"1996","unstructured":"Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K et al. (1996). The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14: 179\u2013205.","journal-title":"Annu Rev Immunol"},{"key":"BF1210368_CR27","first-page":"1083","volume":"62","author":"C Tan","year":"2002","unstructured":"Tan C, Waldmann TA . (2002). Proteasome inhibitor PS-341 a potential therapeutic agent for adult T-cell leukemia. Cancer Res 62: 1083\u20131086.","journal-title":"Cancer Res"},{"key":"BF1210368_CR28","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.1073\/pnas.83.24.9694","volume":"83","author":"M Tsudo","year":"1986","unstructured":"Tsudo M, Kozak RW, Goldman CK, Waldmann TA . (1986). Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci USA 83: 9694\u20139698.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1210368_CR29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.126.4.1393","volume":"126","author":"T Uchiyama","year":"1981","unstructured":"Uchiyama T, Broder S, Waldmann TA . (1981a). A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 126: 1393\u20131397.","journal-title":"J Immunol"},{"key":"BF1210368_CR30","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.4049\/jimmunol.126.4.1398","volume":"126","author":"T Uchiyama","year":"1981","unstructured":"Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA . (1981b). A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells II. Expression of Tac antigen on activated cytotoxic killer T cells suppressor cells and on one of two types of helper T cells. J Immunol 126: 1398\u20131403.","journal-title":"J Immunol"},{"key":"BF1210368_CR31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatuski K, Uchino H . (1977). Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50: 481\u2013492.","journal-title":"Blood"},{"key":"BF1210368_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM199801153380304","volume":"338","author":"F Vincenti","year":"1998","unstructured":"Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. (1998). Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: daclizumab triple therapy study group. N Eng J Med 338: 161\u2013165.","journal-title":"N Eng J Med"},{"key":"BF1210368_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.3008337","volume":"232","author":"TA Waldmann","year":"1986","unstructured":"Waldmann TA . (1986). The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232: 727\u2013732.","journal-title":"Science"},{"key":"BF1210368_CR34","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1146\/annurev.bi.58.070189.004303","volume":"58","author":"TA Waldmann","year":"1989","unstructured":"Waldmann TA . (1989). The multi-subunit interleukin-2 receptor. Annu Rev Biochem 58: 875\u2013911.","journal-title":"Annu Rev Biochem"},{"key":"BF1210368_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.immunol.21.120601.140933","volume":"21","author":"TA Waldmann","year":"2003","unstructured":"Waldmann TA . (2003). The meandering 45-year odyssey of a clinical immunologist. Annu Rev Immunol 21: 1\u201327.","journal-title":"Annu Rev Immunol"},{"key":"BF1210368_CR36","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V72.5.1805.1805","volume":"72","author":"TA Waldmann","year":"1988","unstructured":"Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB et al. (1988). Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805\u20131816.","journal-title":"Blood"},{"key":"BF1210368_CR37","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","volume":"86","author":"TA Waldmann","year":"1995","unstructured":"Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA et al. (1995). Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86: 4063\u20134075.","journal-title":"Blood"},{"key":"BF1210368_CR38","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","volume":"82","author":"TA Waldmann","year":"1993","unstructured":"Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R et al. (1993). The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 82: 1701\u20131712.","journal-title":"Blood"},{"key":"BF1210368_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2165\/00003495-199958060-00006","volume":"58","author":"LR Wiseman","year":"1999","unstructured":"Wiseman LR, Faulds D . (1999). Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 58: 1029\u20131042.","journal-title":"Drugs"},{"key":"BF1210368_CR40","doi-asserted-by":"publisher","first-page":"8227","DOI":"10.1158\/0008-5472.CAN-06-1189","volume":"66","author":"M Zhang","year":"2006","unstructured":"Zhang M, Yao Z, Zhang Z, Garmestani K, Talanov VS, Plascjak PS et al. (2006). The anti-CD25 monoclonal antibody 7G7\/B6, armed with the {alpha}-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 66: 8227\u20138232.","journal-title":"Cancer Res"},{"key":"BF1210368_CR41","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1158\/0008-5472.CAN-04-1088","volume":"64","author":"M Zhang","year":"2004","unstructured":"Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW et al. (2004). Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res 64: 5825\u20135829.","journal-title":"Cancer Res"},{"key":"BF1210368_CR42","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2004-05-1709","volume":"105","author":"M Zhang","year":"2005","unstructured":"Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA . (2005). Combination of therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood 105: 1231\u20131236.","journal-title":"Blood"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1210368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1210368","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1210368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:36:24Z","timestamp":1683855384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1210368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,28]]},"references-count":42,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2007,5,28]]}},"alternative-id":["BF1210368"],"URL":"https:\/\/doi.org\/10.1038\/sj.onc.1210368","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,28]]},"assertion":[{"value":"28 May 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}